Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden.

Begum, N., Stephens, S., Schoeman, O. et al. (5 more authors) (2015) Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4 (2). pp. 131-153. ISSN 2193-8261

Abstract

Metadata

Authors/Creators:
  • Begum, N.
  • Stephens, S.
  • Schoeman, O.
  • Fraschke, A.
  • Kirsch, B.
  • Briere, J.-B.
  • Verheugt, F.W.A.
  • van Hout, B.A.
Copyright, Publisher and Additional Information: © The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Keywords: Acute coronary syndrome; Antiplatelet; Antithrombotic; Cost-effectiveness; Rivaroxaban; Secondary prevention
Dates:
  • Published: December 2015
  • Published (online): 23 June 2015
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 11 May 2017 09:16
Last Modified: 11 May 2017 09:16
Published Version: https://doi.org/10.1007/s40119-015-0041-3
Status: Published
Publisher: Springer Verlag (Germany)
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40119-015-0041-3
Related URLs:

Share / Export

Statistics